Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia
Jonathan Canaani, Avraham Frisch, Daniel A. Pollyea, Marc Schwartz, Shlomzion Aumann, Chezi Ganzel, Arnon Haran, Noa Gross Even‐Zohar, Adir Shaulov, Vladimir Vainstein, Yakir Moshe, Yishai Ofran, Ofir Wolach, Boaz Nachmias
Abstract
OBJECTIVES: Dysregulation of BCL-2 family members has been reported in acute lymphocytic leukemia (ALL), with various BH3-dependencies of the leukemic clone. We conducted a multicenter retrospective cohort of patients with relapsed/refractory B or T ALL, with ven-chemotherapy or ven-navitoclax combinations, to assess efficacy and safety. METHODS: Seventeen patients were included in the analysis, median age was 32 years, with 6 B-ALL and 11 T-ALL patients. Nine patients received venetoclax combined with chemotherapy, and 13 patients received venetoclax in combination with navitoclax, vincristine and asparaginase, of which 5 were already exposed to venetoclax in previous lines. RESULTS: ORR was 55% and 46% among the ven-chemotherapy and the ven-navitoclax-chemotherapy, respectively. Most of the responders proceeded to an allogenic bone marrow transplant in both cohorts. The most common adverse effects of the ven-navitoclax combination were infectious complications and hepatotoxicity. CONCLUSIONS: Our data demonstrated the possible efficacy of ven-chemotherapy and ven-navitoclax in r/r ALL with moderate toxicity.